pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

NEUROCRINE

USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Oldactive not recruitingn=7
  • phase4A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitorrecruitingn=50
  • phase3NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophreniarecruitingn=600
🐶 Hiring Signal
No open roles indexed yet — view NEUROCRINE jobs →

News

  • STAT+: PBMs agree to display TrumpRx drug prices
    Bristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readout
    stat · 1d ago
  • STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
    The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
    stat · 1d ago
  • STAT+: Commure terminates payments under its customer referral programs tied to AI products
    Commure, which develops and sells AI products to clinics, has terminated a program that paid for referrals to new customers.
    stat · 1d ago
  • STAT+: Eli Lilly targets booming black market for retatrutide
    Khartis raises oral immunology funds, Neurocrine drug safety concerns, and more biotech news from The Readout
    stat · 2d ago
  • STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
    When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.
    stat · 2d ago
  • Four questions on new safety warnings for Neurocrine’s Vykat XR
    A group of experts on Prader-Willi syndrome has sounded the alarm on side effects and deaths that may be connected to Neurocrine Biosciences’ medicine Vykat XR. The treatment has been linked to sev…
    endpoints · 2d ago
  • Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
    Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day f…
    biospace · 3d ago
  • STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
    Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide
    stat · 3d ago
  • STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
    Definium Therapeutics said that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.
    stat · 3d ago
  • STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
    German researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment. Now he's co-founding his own company.
    stat · 3d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?